title: Urological complications following use of recombinant human bone morphogenetic protein-2 in anterior lumbar interbody fusion: presented at the 2012 Joint Spine Section Meeting: clinical article.
abstract: OBJECTIVE
  The goal of this study was to compare the urological complications in patients after anterior lumbar interbody fusion (ALIF) with and without the use of recombinant human bone morphogenetic protein-2 (rhBMP-2).
  
  
  METHODS
  The authors retrospectively reviewed the medical records of all patients who underwent ALIF with and without rhBMP-2 between January 2002 and August 2010. Patient demographic, operative, and complication information was analyzed. Male patients who underwent ALIF between L-4 and S-1 were contacted to assess postoperative urological complications.
  
  
  RESULTS
  Of the 110 male patients who underwent ALIF and were included in this study, 59 were treated with rhBMP-2 and 51 did not receive rhBMP-2. The mean follow-up duration was 17.5 months for the rhBMP-2 group and 30.8 months for the control group. No difference was found regarding the total number of urological complications in the rhBMP-2 group versus the control group (22% vs 20%, respectively; p = 1.0) or for retrograde ejaculation specifically (8% vs 8%, respectively; p = 1.0).
  
  
  CONCLUSIONS
  In this study, the use of rhBMP-2 with ALIF surgery was not associated with an increased incidence of urological complications and retrograde ejaculation when compared with control ALIF without rhBMP-2. Further prospective analyses that specifically look at these complications are warranted.
authors.affiliation: Cleveland Clinic Lerner College of Medicine, Center for Spine Health, Departments of Neurological, Cleveland, Ohio 44195, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Lubelski
authors.forename: Kalil G
authors.initials: KG
authors.lastname: Abdullah
authors.forename: Amy S
authors.initials: AS
authors.lastname: Nowacki
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Alvin
authors.forename: Michael P
authors.initials: MP
authors.lastname: Steinmetz
authors.forename: Srita
authors.initials: S
authors.lastname: Chakka
authors.forename: Yumeng
authors.initials: Y
authors.lastname: Li
authors.forename: Nicholas
authors.initials: N
authors.lastname: Gajewski
authors.forename: Edward C
authors.initials: EC
authors.lastname: Benzel
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Mroz
mesh_terms: D000328:Adult; D000368:Aged; D055396:Bone Morphogenetic Protein 2 / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008159:Lumbar Vertebrae / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D013123:Spinal Fusion / Q000009:adverse effects* / Q000295:instrumentation / Q000379:methods; D016212:Transforming Growth Factor beta / Q000009:adverse effects* / Q000627:therapeutic use; D014570:Urologic Diseases / Q000209:etiology*
chemical_list: D055396:Bone Morphogenetic Protein 2; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2